The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Jul 2019 15:34

Arix Bioscience Plc - Holding(s) in Company

Arix Bioscience Plc - Holding(s) in Company

PR Newswire

London, July 8

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Arix Bioscience Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii: No trading in the stock - voting control interest over stock transferred to new managerX
3. Details of person subject to the notification obligationiv
NameWoodford Investment Management Ltd
City and country of registered office (if applicable)9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:05/07/2019
6. Date on which issuer notified (DD/MM/YYYY):08/07/2019
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached19.78%19.78%135,551,850
Position of previous notification (if applicable)21.89%21.89%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)Number of voting rightsix% of voting rights
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BD04507126,819,61719.78%
SUBTOTAL 8. A26,819,61719.78%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights
SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Woodford Investment Management Ltd19.780.0019.78
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
Date of completion08/07/2019
Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.